Cetuximab and panitumumab in a patient with colon cancer and concomitant chronic skin disease: A potential beneficial effect on psoriasis vulgaris

Epidermal growth factor receptor signalling in keratinocyte biology: implications for skin toxicity of tyrosine kinase inhibitors

(2014) Saveria Pastore et al.   ARCHIVES OF TOXICOLOGY

Erythrodermic Psoriasis Improved by Panitumumab, But Not Bevacizumab

(2013) A Nishizawa et al.   ACTA DERMATO-VENEREOLOGICA

Two Cases of Psoriasis Responding to Erlotinib: Time to Revisiting Inhibition of Epidermal Growth Factor Receptor in Psoriasis Therapy?

(2012) Tobias R. Overbeck et al.   DERMATOLOGY

Putting together the psoriasis puzzle: an update on developing targeted therapies

(2012) L. M. Johnson-Huang et al.   Disease Models & Mechanisms

Recommendations on management of EGFR inhibitor-induced skin toxicity: A systematic review

(2011) J.M. Baas et al.   CANCER TREATMENT REVIEWS

Psoriasis induced by cetuximab: A paradoxical adverse effect

(2010) Albert Mas-Vidal et al.   AUSTRALASIAN JOURNAL OF DERMATOLOGY

Elevation of serum epidermal growth factor and interleukin 1 receptor antagonist in active psoriasis vulgaris

(2010) K.S. Anderson et al.   BRITISH JOURNAL OF DERMATOLOGY

Cetuximab Treatment in a Patient with Metastatic Colorectal Cancer and Psoriasis

(2008) Bart Neyns et al.   Current Oncology